Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Soleno Therapeutics Inc (SLNO)

Soleno Therapeutics Inc (SLNO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,231,113
  • Shares Outstanding, K 53,710
  • Annual Sales, $ 0 K
  • Annual Income, $ -175,850 K
  • EBIT $ -89 M
  • EBITDA $ -87 M
  • 60-Month Beta -3.12
  • Price/Sales 20.42
  • Price/Cash Flow N/A
  • Price/Book 4.62

Options Overview Details

View History
  • Implied Volatility 75.42% (-3.69%)
  • Historical Volatility 43.33%
  • IV Percentile 64%
  • IV Rank 19.75%
  • IV High 218.78% on 03/26/25
  • IV Low 40.13% on 08/14/25
  • Expected Move (DTE 3) 3.78 (9.11%)
  • Put/Call Vol Ratio 0.56
  • Today's Volume 3,337
  • Volume Avg (30-Day) 1,861
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 52,499
  • Open Int (30-Day) 50,167
  • Expected Range 37.76 to 45.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.53
  • Number of Estimates 6
  • High Estimate 0.70
  • Low Estimate 0.45
  • Prior Year -1.27
  • Growth Rate Est. (year over year) +141.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.00 +3.85%
on 01/12/26
52.85 -21.39%
on 12/15/25
-10.46 (-20.12%)
since 12/12/25
3-Month
40.00 +3.85%
on 01/12/26
72.88 -43.00%
on 10/16/25
-22.22 (-34.84%)
since 10/10/25
52-Week
40.00 +3.85%
on 01/12/26
90.32 -54.01%
on 07/09/25
-1.57 (-3.64%)
since 01/10/25

Most Recent Stories

More News
SLNO Investors: Contact Kirby McInerney LLP About Investigation into Soleno Therapeutics, Inc.

The law firm of Kirby McInerney LLP continues its investigation on behalf of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:SLNO) investors concerning the Company’s...

SLNO : 41.54 (-3.40%)
Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results

REDWOOD CITY, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...

SLNO : 41.54 (-3.40%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are...

SLNO : 41.54 (-3.40%)
Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism

REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...

SLNO : 41.54 (-3.40%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

NEW YORK , Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are...

SLNO : 41.54 (-3.40%)
Soleno Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (SLNO)

The law firm of Kirby McInerney LLP is investigating potential claims against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:SLNO). The investigation concerns whether...

SLNO : 41.54 (-3.40%)
Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses

SAN DIEGO , Dec. 15, 2025 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Soleno Therapeutics, Inc. (NASDAQ: SLNO) or certain of its officers and directors...

SLNO : 41.54 (-3.40%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

NEW YORK , Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised...

SLNO : 41.54 (-3.40%)
Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses

SAN DIEGO , Dec. 4, 2025 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Soleno Therapeutics, Inc. (NASDAQ: SLNO) or certain of its officers and directors...

SLNO : 41.54 (-3.40%)
Soleno Therapeutics Announces the Passing of Board Member William G. Harris

REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...

SLNO : 41.54 (-3.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Soleno Therapeutics Inc. is a healthcare company. It develops and commercializes diagnostics, devices and therapeutics addressing unmet medical needs. The Company offers products consists of CoSense end-tidal carbon monoxide Monitor, NeoPIP Infant Resuscitator and Accessories and Serenz Nasal Relief....

See More

Key Turning Points

3rd Resistance Point 50.12
2nd Resistance Point 47.79
1st Resistance Point 44.66
Last Price 41.54
1st Support Level 39.21
2nd Support Level 36.88
3rd Support Level 33.75

See More

52-Week High 90.32
Fibonacci 61.8% 71.10
Fibonacci 50% 65.16
Fibonacci 38.2% 59.22
Last Price 41.54
52-Week Low 40.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar